KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...
Cambridge Independent6 天
$31m seed round success fires up TRIMTECH Therapeutics’ mission
From its base at the Milner Therapeutics Institute, TRIMTECH is developing a pipeline of potent, CNS (central nervous system) ...